PressSeptember 13, 2022 Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
PressSeptember 13, 2022 Revitalist and Wake Network Enter Joint Venture Offering National and International Access to Psychedelics for Veterans
PressSeptember 12, 2022 Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
PressSeptember 12, 2022 Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home
PressSeptember 12, 2022 Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
PressSeptember 8, 2022 Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
PressSeptember 8, 2022 Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History
PressSeptember 8, 2022 MindMed Announces Positive Results from Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
PressSeptember 8, 2022 Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
PressSeptember 7, 2022 Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds
PressSeptember 7, 2022 Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries
PressSeptember 7, 2022 Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global
PressSeptember 7, 2022 PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
PressSeptember 3, 2022 Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
PressSeptember 2, 2022 Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
PressSeptember 1, 2022 Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
PressSeptember 1, 2022 PanGenomic Health Inc Signs a Non-binding Letter of Intent for the Acquisition of Mindleap Health Inc.
